Ebola
12
0
0
11
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (12)
Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
A Study of a New Vaccine Against Two Types of Ebola
Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)
A Study in Tanzania of a New Vaccine Against Two Types of Ebola
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study